A Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Condition:   Conjunctivitis, Allergic Interventions:   Drug: Reproxalap Ophthalmic Solution (0.25%);   Drug: Reproxalap Ophthalmic Solution (0.5%);   Drug: Vehicle Ophthalmic Solution Sponsor:   Aldeyra Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RdT1mg